GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eutilex Co Ltd (XKRX:263050) » Definitions » Profitability Rank

Eutilex Co (XKRX:263050) Profitability Rank : 1 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eutilex Co Profitability Rank?

Eutilex Co has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Eutilex Co's Operating Margin % for the quarter that ended in Mar. 2024 was -2,054.93%. As of today, Eutilex Co's Piotroski F-Score is 4.


Competitive Comparison of Eutilex Co's Profitability Rank

For the Biotechnology subindustry, Eutilex Co's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eutilex Co's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eutilex Co's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Eutilex Co's Profitability Rank falls into.



Eutilex Co Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Eutilex Co has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Eutilex Co's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-6498.791 / 316.254
=-2,054.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Eutilex Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Eutilex Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -62.9%.

4. Consistency of the profitability

5. Predictability Rank


Eutilex Co Profitability Rank Related Terms

Thank you for viewing the detailed overview of Eutilex Co's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Eutilex Co (XKRX:263050) Business Description

Traded in Other Exchanges
N/A
Address
Daeryung Technotown 17, Suite 1401, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, KOR, 08594
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.

Eutilex Co (XKRX:263050) Headlines

No Headlines